600380.SSJoincare Pharmaceutical Group Industry Co.,Ltd.
The schedule
- Thu22Oct
Q3 2026 reporting, providing a read-through on Q4 guidance and active pharmaceutical ingredient (API) export resilience amidst shifting global trade policies.
- Fri20Nov
Conclusion of China's annual National Reimbursement Drug List (NRDL) updates, dictating pricing and volume access for Joincare's newer specialty formulations.
- Tue15Dec
Anticipated year-end board signaling regarding share repurchases or special dividends, forced by an irrational valuation gap.
- Thu25Mar
Full-year 2026 results and 2027 initial guidance. This print will definitively show whether the VBP overhang has passed and top-line growth is returning.
Past
- Fri28Aug
Actual outcome: Bear · $9.24 at outcome
Price reached or fell below bear floor ($9.15) at outcome date.
Expected H1 2026 earnings announcement. Focus will be on whether the ongoing top-line decay (-8.99% YoY) and net income contraction (-4.78% YoY) are accelerating or stabilizing under domestic generic pricing pressures.